Harbourvest Partners’s ImmunityBio IBRX Stock Holding History

Harbourvest Partners’s Portfolio IBRX Stock Details IBRX Fund Activity

Bought

Maintained

Sold

Quarter	Market Value	Status	Shares	Change in Stake	Trade Value	Portfolio Weight	Portfolio Position
2024 Q4	–	Sell	-335,709	Closed	-$1.25M	–	27
2024 Q3	$1.25M	Hold	335,709	–	–	0.65%	18
2024 Q2	$2.12M	Hold	335,709	–	–	1.13%	9
2024 Q1	$1.8M	Hold	335,709	–	–	0.82%	17
2023 Q4	$1.69M	Hold	335,709	–	–	0.56%	22
2023 Q3	$567K	Hold	335,709	–	–	0.19%	41
2023 Q2	$933K	Hold	335,709	–	–	0.27%	36
2023 Q1	$611K	Hold	335,709	–	–	0.21%	41
2022 Q4	$1.7M	Hold	335,709	–	–	0.57%	22
2022 Q3	$1.67M	Hold	335,709	–	–	0.55%	23
2022 Q2	$1.25M	Hold	335,709	–	–	0.41%	32
2022 Q1	$1.88M	Hold	335,709	–	–	0.38%	34
2021 Q4	$2.04M	Hold	335,709	–	–	0.26%	34
2021 Q3	$3.27M	Hold	335,709	–	–	0.31%	23
2021 Q2	$4.79M	Sell	335,709 -11,300	-3%	-$187K	0.46%	21
2021 Q1	$8.24M	Buy	+347,009	New	+$9M	1.1%	13

Other funds holding IBRX

Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return

BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return

State Street Boston, Massachusetts $2.9T AUM 29.55% 1-Year Est. Return

Morgan Stanley New York $1.66T AUM 25.57% 1-Year Est. Return

Geode Capital Management Boston, Massachusetts $1.61T AUM 30.72% 1-Year Est. Return

Woodline Partners San Francisco, California $26.4B AUM 44.85% 1-Year Est. Return

CAM

Cormorant Asset Management Boston, Massachusetts $1.99B AUM 737.95% 1-Year Est. Return

TCM

Tang Capital Management San Diego, California $1.97B AUM 125.1% 1-Year Est. Return

UBS Group Zurich, Switzerland $666B AUM 30.12% 1-Year Est. Return

Northern Trust Chicago, Illinois $757B AUM 28.64% 1-Year Est. Return

Harbourvest Partners's IBRX Position: Q4 2024 in Review

Harbourvest Partners sold out of ImmunityBio (IBRX) in Q4 2024, closing a stake of 335,709 shares — an estimated $1.25M sold.

Harbourvest Partners first reported a position in IBRX in Q1 2021 and held it in 15 quarters. The position peaked at $8.24M in Q1 2021. 201 funds tracked by Wall St. Rank hold IBRX as of Q4 2024.

Harbourvest Partners reported no remaining ImmunityBio position as of Q4 2024 after selling out during the quarter.
Harbourvest Partners sold 335,709 ImmunityBio shares in Q4 2024, an estimated $1.25M.
Harbourvest Partners first reported a position in ImmunityBio in Q1 2021 and held it in 15 quarters.
Harbourvest Partners's ImmunityBio position peaked at $8.24M in Q1 2021.
201 funds tracked by Wall St. Rank held ImmunityBio as of Q4 2024.

Based on Harbourvest Partners's 13F filing for Q4 2024, filed 14 Feb 2025.